A Branched-chain Amino Acid Formula “LIVACT® Granules” Launches in Vietnam

Ajinomoto Pharmaceuticals Co., Ltd. (“Ajinomoto Pharmaceuticals”) (President, Takashi Nagamachi; Headquarters, Tokyo, Japan) launches a branched-chain amino acid formula “LIVACT® Granules” in the Vietnam market as of August 3, 2015, following the obtainment of import and marketing permission of “LIVACT® Granules” in the country on February 9, 2015.

LIVACT® Granules” - a granular formula that contains branched-chain amino acids (L-valine, L-leucine and L-isoleucine) – is an ethical pharmaceutical product indicated for improvement of hypoalbuminemia in patients with decompensated liver cirrhosis who are suffering from hypoalbuminemia regardless of sufficient dietary intake. In a cohort clinical study conducted in Japan, “LIVACT® Granules” has been proven to prevent severe complications that can occur with progression of liver cirrhosis.

Under a distributorship agreement with DKSH Group for the Vietnam market, Ajinomoto Pharmaceuticals deployed dedicated marketing staff and medical representatives for the products of Ajinomoto Pharmaceuticals in the local affiliate of DKSH Group and started marketing activities for “MORIHEPAMIN® Infusion” – an amino acid injection for hepatic failure – and “NEOAMIYU® Infusion” – an amino acid injection for renal failure – in April 2012. Ajinomoto Pharmaceuticals also launched a long-acting calcium channel blocker antihypertensive “ATELEC® Tab.” in January 2013 and an essential amino acids preparation for renal failure “Amiyu® Granule” in November 2013 in the same country.

Ajinomoto Pharmaceuticals desires to make a contribution to treatment of patients with decompensated liver cirrhosis in Vietnam by the launch of “LIVACT® Granules”.

As a member company of the Ajinomoto Group that aims to be “a group of companies that contributes to human health globally”, Ajinomoto Pharmaceuticals has focused on Southeast Asia for overseas business because the Ajinomoto Group is well known in the region and there are similarities in the food culture background and the physical constitution between the people there and Japanese, which will facilitate application of knowledge obtained in Japan.

Among the Southeast Asian countries, Ajinomoto Pharmaceuticals particularly concentrates its marketing efforts on the Vietnam market, since the country has achieved remarkable economic growth and Ajinomoto Pharmaceuticals had launched its products in the country in the past.

In Vietnam also, Ajinomoto Pharmaceuticals will be committed to increase of quality of life of patients through practice of “For Your Quality Of Life”.

(continue overleaf)
About Ajinomoto Pharmaceuticals Co., Ltd.
Ajinomoto Pharmaceuticals is focused on development of new pharmaceuticals, improvement of existing pharmaceuticals, fulfillment of unmet medical needs and providing medical information in the area of amino acid-related pharmaceuticals that were born from application of amino acid-related knowledge cultivated in the Ajinomoto Group, particularly in the gastrointestinal disease area.

About DKSH Group

DKSH Group is a leading company group that provides “Market Expansion Services” globally centered in Asia. In 35 countries over the world, DKSH Group has 750 offices with 27,600 experts achieving 9.8 billion sales in Swiss Franc in 2014. DKSH Group shares have been listed on SIX Swiss Exchange since 2012. The healthcare division of DKSH Group provides a wide range of solutions covering product registration, market research, marketing, sales, distribution, logistics and collection of receivables of prescription drugs, OTC and medical devices for those companies who want to expand their business in Asia.

【Contact】
Ajinomoto Pharmaceuticals Co., Ltd.
Corporate Planning Dept.
TEL: +81-(0)3-6280-9802
E-mail: contact_ajs@ajinomoto.com